MRVI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Maravai LifeSciences Reports Third Quarter 2026 Financial Results and Raises Full Year Guidance

Nov 4, 2026

8-K

Maravai LifeSciences Holdings, Inc. Announces Second Quarter 2026 Financial Results

Aug 6, 2026

8-K

Maravai LifeSciences Refinances Credit Agreement, Reducing Debt and Extending Maturity to 2032

Jun 3, 2026

8-K

Maravai LifeSciences Holdings, Inc. Announces Results of 2026 Annual Meeting of Shareholders

May 29, 2026

8-K

Maravai LifeSciences Reports First Quarter 2026 Financial Results and Raises Full-Year Guidance

May 7, 2026

8-K

Maravai LifeSciences Reports Q4 and Full Year 2025 Results, Exceeds Q4 Revenue Expectations

Feb 25, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

20,000,000 Shares-

Sep 13, 2021

424B4

18,000,000 Shares-

Apr 9, 2021

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Nov 23, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 12, 2025

S-1

20,000,000 Shares- EFFECTIVE

Sep 7, 2021

DRS

Form DRS - Draft Registration Statement

Aug 26, 2021

S-1MEF

Registration-

Apr 7, 2021

S-1/A

On November 19, 2020, we issued 168,654,981 shares of Class B common stock to MLSH 1.- EFFECTIVE

Apr 6, 2021

S-1

15,000,000 Shares- EFFECTIVE

Apr 5, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A